{"filing":{"accession_number":"0001193125-26-338080","cik":"0001555280","ticker":"ZTS","company_name":"Zoetis Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"d166736d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1555280/000119312526338080/d166736d8k.htm"},"events":[{"id":25645,"run_id":23274,"accession_number":"0001193125-26-338080","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"James Saccaro's appointment as Executive Vice President, Chief Financial Officer and Chief Operating Officer effective August 17, 2026 is the principal disclosed action. While the filing also discloses Wetteny Joseph's departure, the appointment of a new CFO/COO at a major public company (Zoetis, a large-cap animal health leader) is the salient event. The compensation details (base salary $1M, LTI target $5M, make-whole awards totaling $7.5M) and his extensive background at GE HealthCare and Baxter underscore the materiality of this executive leadership transition.","company_name":"Zoetis Inc.","ticker":"ZTS","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26531,"accession_number":"0001193125-26-338080","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"James Saccaro's appointment as Executive Vice President, Chief Financial Officer and Chief Operating Officer effective August 17, 2026 is the principal disclosed action. While the filing also discloses Wetteny Joseph's departure, the appointment of a new CFO/COO at a major public company (Zoetis, a large-cap animal health leader) is the salient event. The compensation details (base salary $1M, LTI target $5M, make-whole awards totaling $7.5M) and his extensive background at GE HealthCare and Baxter underscore the materiality of this executive leadership transition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:19:42.531622+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26531,"accession_number":"0001193125-26-338080","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"James Saccaro's appointment as Executive Vice President, Chief Financial Officer and Chief Operating Officer effective August 17, 2026 is the principal disclosed action. While the filing also discloses Wetteny Joseph's departure, the appointment of a new CFO/COO at a major public company (Zoetis, a large-cap animal health leader) is the salient event. The compensation details (base salary $1M, LTI target $5M, make-whole awards totaling $7.5M) and his extensive background at GE HealthCare and Baxter underscore the materiality of this executive leadership transition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:19:42.531622+00:00","company_name":"Zoetis Inc.","ticker":"ZTS","filing_date":"2026-08-06"}]}